Jubilant Pharmova Limited (BOM:530019)
India · Delayed Price · Currency is INR 866.05
+1.60 (0.19%)
At close: Aug 17, 2026
Jubilant Pharmova Financials Overview
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
| Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Revenue Revenue Growth | 86,083 | 82,796 | 72,345 | 67,029 | 62,817 | 61,302 |
Revenue Growth | 16.27% | 14.45% | 7.93% | 6.71% | 2.47% | 0.52% |
Gross Profit Gross Profit Growth | 55,935 | 53,953 | 46,988 | 43,516 | 42,001 | 46,422 |
Operating Income Operating Income Growth | 7,486 | 8,194 | 8,068 | 5,231 | 3,749 | 8,398 |
Net Income Net Income Growth | 3,521 | 3,985 | 8,394 | 771 | -610 | 4,139 |
Earnings Per Share EPS Growth | 22.17 | 25.08 | 52.85 | 4.86 | -3.83 | 26.00 |
EPS Growth | -23.46% | -52.54% | 987.45% | - | - | -50.46% |
| Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Radio Pharma Radio Pharma Growth | 38,436 | 36,901 | 33,880 | 30,013 | 25,524 | 21,228 |
Allergy Immunotherapy Allergy Immunotherapy Growth | 8,187 | 7,957 | 7,142 | 6,977 | 6,027 | 4,894 |
Contract Development and Manufacturing Organization - Sterile Injectables Contract Development and Manufacturing Organization - Sterile Injectables Growth | 19,398 | 18,126 | 13,527 | 12,044 | 12,710 | 14,351 |
Contract Research, Development and Manufacturing Organization Contract Research, Development and Manufacturing Organization Growth | 12,793 | 12,649 | 11,728 | 11,400 | 12,928 | 11,483 |
Generics Generics Growth | 7,809 | 7,735 | 6,853 | 7,746 | 7,652 | 11,616 |
Inter-Segment Inter-Segment Growth | -1,139 | -1,157 | -1,157 | -1,534 | -2,280 | -2,491 |
Unallocable Corporate Unallocable Corporate Growth | 599 | 585 | 372 | 383 | 218 | 202.49 |
Total Total Growth | 86,083 | 82,796 | 72,345 | 67,029 | 62,817 | 61,302 |
| Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Cash & Investments Cash & Investments Growth | 12,671 | 12,671 | 10,883 | 9,564 | 10,139 | 9,892 |
Total Debt Total Debt Growth | 36,147 | 36,147 | 27,310 | 36,640 | 36,768 | 31,920 |
Net Cash (Debt) Net Cash Growth | -23,476 | -23,476 | -16,427 | -27,076 | -26,629 | -22,028 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share Net Cash Per Share Growth | -147.82 | -147.75 | -103.40 | -170.44 | -167.32 | -138.39 |
| Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Cash Flow Operating Cash Flow Growth | - | 12,268 | 10,721 | 9,713 | 6,607 | 8,375 |
Capital Expenditures CapEx Growth | - | -14,491 | -11,156 | -8,977 | -8,145 | -6,000 |
Free Cash Flow Free Cash Flow Growth | - | -2,223 | -435 | 736 | -1,538 | 2,376 |
Free Cash Flow Growth | - | - | - | - | - | -81.10% |
| Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Gross Margin | 64.98% | 65.16% | 64.95% | 64.92% | 66.86% | 75.73% |
Operating Margin | 8.70% | 9.90% | 11.15% | 7.80% | 5.97% | 13.70% |
Pretax Margin | 6.34% | 7.42% | 13.55% | 2.54% | 0.44% | 10.28% |
Profit Margin | 4.09% | 4.81% | 11.60% | 1.15% | -0.97% | 6.75% |
FCF Margin | - | -2.69% | -0.60% | 1.10% | -2.45% | 3.88% |
| Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 17, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Dividend Per Share Dividend Per Share Growth | 5.000 | 5.000 | 5.000 | 5.000 | 5.000 | 5.000 |
Dividend Per Share Growth | 0% | 0% | 0% | 0% | 0% | 0% |
Dividend Yield | 0.58% | 0.62% | 0.56% | 0.89% | 1.84% | 1.34% |
| Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 17, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
PE Ratio | 38.99 | 32.45 | 16.84 | 117.29 | - | 14.92 |
Forward PE | 25.64 | 24.10 | 24.94 | 14.22 | 9.99 | 11.22 |
P/FCF Ratio | - | - | - | 122.87 | - | 25.99 |
PS Ratio | 1.59 | 1.56 | 1.95 | 1.35 | 0.71 | 1.01 |